Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
DR30303
i
Other names:
DR30303
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Huadong Medicine
Drug class:
CLDN18.2 inhibitor
Related drugs:
‹
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AZD5863 (3)
AB011 (2)
ASP2138 (2)
TST001 (2)
MIL93 (1)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
FL-301 (0)
IBI-389 (0)
IBI360 (0)
LB4330 (0)
LM-102 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
QLS31905 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
AMG 910 (0)
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AZD5863 (3)
AB011 (2)
ASP2138 (2)
TST001 (2)
MIL93 (1)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
FL-301 (0)
IBI-389 (0)
IBI360 (0)
LB4330 (0)
LM-102 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
QLS31905 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
AMG 910 (0)
›
Associations
News
Trials
Filter by
Latest
4ms
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=94, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial primary completion date: Jun 2024 --> Jun 2025
4 months ago
Trial primary completion date • Metastases
|
CLDN18 (Claudin 18)
|
DR30303
10ms
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=94, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Sep 2023 --> Jun 2024
10 months ago
Trial completion date • Trial primary completion date • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
DR30303
almost2years
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=94, Recruiting, Zhejiang Doer Biologics Co., Ltd.
almost 2 years ago
New P1 trial • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
DR30303
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login